Long-Term Efficacy and Low Adverse Events of Methylprednisolone Pulses Combined to Low-Dose Glucocorticoids for Systemic Sclerosis: A Retrospective Clinical Study of 10 Years’ Follow-Up

References

• Varga J, Trojanowska M, Kuwana M, et al. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017;2:137–152. doi:10.5301/jsrd.5000249
   Web of Science ®Google Scholar
• Smith V, Scirè CA, Talarico R, et al. Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open. 2018;4(Suppl 1):e000782. doi:10.1136/rmdopen-2018-000782
   PubMed Web of Science ®Google Scholar
• Ruaro B, Sulli A, Pizzorni C, et al. Correlations between blood perfusion and dermal thickness in different skin areas of systemic sclerosis patients. Microvasc Res. 2018;115:28–33. doi:10.1016/j.mvr.2017.08.004
   PubMed Web of Science ®Google Scholar
• Maehara T, Kaneko N, Perugino CA, et al. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest. 2020;130(5):2451–2464. doi:10.1172/JCI131700
   PubMed Web of Science ®Google Scholar
• Asano Y. Systemic sclerosis. J Dermatol. 2018;45(2):128–138. doi:10.1111/1346-8138.14153
   PubMed Web of Science ®Google Scholar
• Iudici M, van der Goes MC, Valentini G, Bijlsma JWJ. Glucocorticoids in systemic sclerosis: weighing up the benefits and risks -A systematic review. Clin Exp Rheumatol. 2013;31(2 Suppl 76):157.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol. 2002;29(11):2371–2378.
   PubMed Web of Science ®Google Scholar
• Vanthuyne M, Blockmans D, Westhovens R, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287–292.
   PubMed Web of Science ®Google Scholar
• Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology. 2018;23(11):1041–1048. doi:10.1111/resp.13365
   PubMed Web of Science ®Google Scholar
• Iudici M, Fasano S, Iacono D, Russo B, Cuomo G, Valentini G. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol. 2014;33(2):153–164. doi:10.1007/s10067-013-2422-0
   PubMed Web of Science ®Google Scholar
• Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019;30(6):1145–1156. doi:10.1007/s00198-019-04906-x
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613–1619. doi:10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• EUSTAR collaborators, Bütikofer L, Varisco PA, Distler O, et al. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-A EUSTAR analysis. Arthritis Res Ther. 2020;22(1):59. doi:10.1186/s13075-020-2141-2
   PubMed Web of Science ®Google Scholar
• Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - A systematic review. Clin Exp Rheumatol. 2013;31(2):157–165.
   PubMed Web of Science ®Google Scholar
• Iudici M. What should clinicians know about the use of glucocorticoids in systemic sclerosis? Mod Rheumatol. 2017;27(6):919–923. doi:10.1080/14397595.2016.1270796
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology. 2014;53:1742–1751. doi:10.1093/rheumatology/keu135
   PubMed Web of Science ®Google Scholar
• Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid Adverse Effects. StatPearls; 2021.
   Google Scholar
• Thiebaut M, Launay D, Rivière S, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17(6):582–587. doi:10.1016/j.autrev.2017.12.010
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909
   PubMed Web of Science ®Google Scholar
• Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424
   PubMed Web of Science ®Google Scholar
• Weusten BL, Jacobs JW, Bijlsma JW. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum. 1993;23:183–192. doi:10.1016/S0049-0172(05)80039-3
   PubMed Web of Science ®Google Scholar
• Kimberly RP. Pulse methylprednisolone in SLE. Clin Rheum Dis. 1982;8(1):261–278. doi:10.1016/S0307-742X(21)00212-5
   PubMedGoogle Scholar
• Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2:11–18. doi:10.5301/jsrd.5000231
   PubMed Web of Science ®Google Scholar
• Orlandi M, Landini N, Sambataro G, et al. The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology. 2022;61(4):1600–1609. PMID: 34320649. doi:10.1093/rheumatology/keab615
   PubMed Web of Science ®Google Scholar
• Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N. Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients. Quant Imaging Med Surg. 2016;6(4):381–390. doi:10.21037/qims.2016.08.08
   PubMed Web of Science ®Google Scholar
• Adler S, Huscher D, Siegert E, et al.; EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20(1):17. doi:10.1186/s13075-018-1517-z
   PubMed Web of Science ®Google Scholar
• Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol. 1987;9(3):549–554. doi:10.1016/S0735-1097(87)80047-5
   PubMed Web of Science ®Google Scholar
• Fan Y, Wang D, Rao C, et al. Atorvastatin combined with low-dose dexamethasone treatment protects endothelial function impaired by chronic subdural hematoma via the transcription factor KLF-2. Drug Des Devel Ther. 2020;14:3291–3299. doi:10.2147/DDDT.S256050
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al.; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528. PMID: 31112379. doi:10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Maher TM, Mayes MD, Kreuter M, et al. Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73(4):671–676. doi:10.1002/art.41576
   PubMed Web of Science ®Google Scholar
• Wigley FM, Boin F. Clinical features and treatment of scleroderma. In: Kelley and Firestein’s Textbook of Rheuma-Tology. 10th ed; 2017:1424–1460.
   Google Scholar
• Connolly MK. Systemic sclerosis (scleroderma): remaining challenges. Ann Transl Med. 2021;9(5):438. doi:10.21037/atm-20-5449
   PubMed Web of Science ®Google Scholar
• German Network for Systemic Scleroderma Centers, Hunzelmann N, Moinzadeh P, Genth E, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther. 2009;11(2):R30. doi:10.1186/ar2634
   PubMed Web of Science ®Google Scholar